BRPI0610956A2 - derivados de benzofurano com atividades terapêuticas - Google Patents

Info

Publication number

BRPI0610956A2

BRPI0610956A2 BRPI0610956-0A BRPI0610956A BRPI0610956A2 BR PI0610956 A2 BRPI0610956 A2 BR PI0610956A2 BR PI0610956 A BRPI0610956 A BR PI0610956A BR PI0610956 A2 BRPI0610956 A2 BR PI0610956A2

Authority

BR

Brazil

Prior art keywords

hexahydro

dimethylptyl

group

dimethylpentyl

dibenzofuran

Prior art date

2005-05-31

Links

• Espacenet
• Global Dossier
• Discuss

• 230000001225 therapeutic effect Effects 0.000 title abstract description 21
• 150000001907 coumarones Chemical class 0.000 title abstract description 8
• 150000001875 compounds Chemical class 0.000 claims abstract description 395
• 238000000034 method Methods 0.000 claims abstract description 92
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 42
• -1 1,1-dimethylpentyl Chemical group 0.000 claims description 231
• 239000001257 hydrogen Substances 0.000 claims description 151
• 229910052739 hydrogen Inorganic materials 0.000 claims description 151
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 140
• 229920006395 saturated elastomer Polymers 0.000 claims description 127
• 150000002431 hydrogen Chemical group 0.000 claims description 100
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 62
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 61
• 239000000243 solution Substances 0.000 claims description 57
• 150000002148 esters Chemical class 0.000 claims description 55
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 49
• 239000002253 acid Substances 0.000 claims description 46
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 45
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
• 208000002193 Pain Diseases 0.000 claims description 42
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 42
• 150000003839 salts Chemical class 0.000 claims description 38
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
• 150000002923 oximes Chemical class 0.000 claims description 29
• 229910052799 carbon Inorganic materials 0.000 claims description 28
• 125000004122 cyclic group Chemical group 0.000 claims description 27
• IKTRNOZMSJUISH-UHFFFAOYSA-N azulen-4-ol Chemical compound OC1=CC=CC=C2C=CC=C12 IKTRNOZMSJUISH-UHFFFAOYSA-N 0.000 claims description 26
• 239000003814 drug Substances 0.000 claims description 25
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
• 125000000623 heterocyclic group Chemical group 0.000 claims description 23
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
• 235000019439 ethyl acetate Nutrition 0.000 claims description 22
• 239000004480 active ingredient Substances 0.000 claims description 20
• 125000003118 aryl group Chemical group 0.000 claims description 20
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
• 239000011630 iodine Substances 0.000 claims description 18
• 229910052740 iodine Inorganic materials 0.000 claims description 18
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 17
• 229910052736 halogen Inorganic materials 0.000 claims description 17
• 150000002367 halogens Chemical class 0.000 claims description 17
• 239000012453 solvate Substances 0.000 claims description 17
• 230000002757 inflammatory effect Effects 0.000 claims description 16
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 15
• 206010028980 Neoplasm Diseases 0.000 claims description 15
• 125000000217 alkyl group Chemical group 0.000 claims description 15
• 125000003324 azulen-4-yl group Chemical group [H]C1=C([H])C2=C(*)C([H])=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 14
• 238000002360 preparation method Methods 0.000 claims description 14
• 206010061218 Inflammation Diseases 0.000 claims description 12
• 230000004054 inflammatory process Effects 0.000 claims description 12
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 11
• 239000003085 diluting agent Substances 0.000 claims description 11
• TZEIAPXWECOJGT-UHFFFAOYSA-N 1h-inden-4-ol Chemical compound OC1=CC=CC2=C1C=CC2 TZEIAPXWECOJGT-UHFFFAOYSA-N 0.000 claims description 10
• 210000003169 central nervous system Anatomy 0.000 claims description 10
• 125000005842 heteroatom Chemical group 0.000 claims description 10
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
• DITZKPGGPGEQCE-UHFFFAOYSA-N azulene-5-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=CC=CC2=C1 DITZKPGGPGEQCE-UHFFFAOYSA-N 0.000 claims description 9
• 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims description 9
• 229910052757 nitrogen Inorganic materials 0.000 claims description 9
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 9
• 208000023275 Autoimmune disease Diseases 0.000 claims description 8
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
• 125000004429 atom Chemical group 0.000 claims description 8
• 125000004432 carbon atom Chemical group C* 0.000 claims description 8
• 230000001684 chronic effect Effects 0.000 claims description 8
• 230000006378 damage Effects 0.000 claims description 8
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
• 230000002093 peripheral effect Effects 0.000 claims description 8
• 210000001519 tissue Anatomy 0.000 claims description 8
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
• 208000012902 Nervous system disease Diseases 0.000 claims description 7
• 208000025966 Neurological disease Diseases 0.000 claims description 7
• 201000011510 cancer Diseases 0.000 claims description 7
• 239000000839 emulsion Substances 0.000 claims description 7
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 7
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 6
• PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 claims description 6
• 208000027559 Appetite disease Diseases 0.000 claims description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
• 206010020751 Hypersensitivity Diseases 0.000 claims description 6
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
• 230000001154 acute effect Effects 0.000 claims description 6
• 150000004702 methyl esters Chemical class 0.000 claims description 6
• 201000006417 multiple sclerosis Diseases 0.000 claims description 6
• 230000004770 neurodegeneration Effects 0.000 claims description 6
• 230000009278 visceral effect Effects 0.000 claims description 6
• FNBDPHKBUBKFCO-UHFFFAOYSA-N 2-(2-phenylethyl)-1,3-dithiolane Chemical compound S1CCSC1CCC1=CC=CC=C1 FNBDPHKBUBKFCO-UHFFFAOYSA-N 0.000 claims description 5
• 208000020084 Bone disease Diseases 0.000 claims description 5
• 208000011231 Crohn disease Diseases 0.000 claims description 5
• 208000019695 Migraine disease Diseases 0.000 claims description 5
• 208000001132 Osteoporosis Diseases 0.000 claims description 5
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 5
• 206010003246 arthritis Diseases 0.000 claims description 5
• 208000006673 asthma Diseases 0.000 claims description 5
• 239000002895 emetic Substances 0.000 claims description 5
• 206010027599 migraine Diseases 0.000 claims description 5
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
• YHBWXWLDOKIVCJ-UHFFFAOYSA-N 2-[2-(2-methoxyethoxy)ethoxy]acetic acid Chemical compound COCCOCCOCC(O)=O YHBWXWLDOKIVCJ-UHFFFAOYSA-N 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 4
• 201000001320 Atherosclerosis Diseases 0.000 claims description 4
• 201000006474 Brain Ischemia Diseases 0.000 claims description 4
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
• 208000006561 Cluster Headache Diseases 0.000 claims description 4
• 208000010412 Glaucoma Diseases 0.000 claims description 4
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
• 208000023105 Huntington disease Diseases 0.000 claims description 4
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
• 208000019693 Lung disease Diseases 0.000 claims description 4
• 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 4
• 201000009906 Meningitis Diseases 0.000 claims description 4
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
• 208000009525 Myocarditis Diseases 0.000 claims description 4
• 206010028813 Nausea Diseases 0.000 claims description 4
• 208000018737 Parkinson disease Diseases 0.000 claims description 4
• 201000004681 Psoriasis Diseases 0.000 claims description 4
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
• 208000005392 Spasm Diseases 0.000 claims description 4
• 208000006011 Stroke Diseases 0.000 claims description 4
• 206010044565 Tremor Diseases 0.000 claims description 4
• 206010047700 Vomiting Diseases 0.000 claims description 4
• 230000002159 abnormal effect Effects 0.000 claims description 4
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
• 230000004097 bone metabolism Effects 0.000 claims description 4
• 206010008118 cerebral infarction Diseases 0.000 claims description 4
• 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
• UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 claims description 4
• 206010014599 encephalitis Diseases 0.000 claims description 4
• 206010014665 endocarditis Diseases 0.000 claims description 4
• 208000006454 hepatitis Diseases 0.000 claims description 4
• 231100000283 hepatitis Toxicity 0.000 claims description 4
• 206010028417 myasthenia gravis Diseases 0.000 claims description 4
• 230000008693 nausea Effects 0.000 claims description 4
• 230000002314 neuroinflammatory effect Effects 0.000 claims description 4
• 210000000056 organ Anatomy 0.000 claims description 4
• 201000008482 osteoarthritis Diseases 0.000 claims description 4
• 229910052760 oxygen Inorganic materials 0.000 claims description 4
• 208000008494 pericarditis Diseases 0.000 claims description 4
• 239000004094 surface-active agent Substances 0.000 claims description 4
• 230000008673 vomiting Effects 0.000 claims description 4
• ZYZKQOMUFDURCI-UHFFFAOYSA-N 6-hydroxyimino-3-(2-methylhexan-2-yl)-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1-ol Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCCC2=NO ZYZKQOMUFDURCI-UHFFFAOYSA-N 0.000 claims description 3
• JVISSGBRRMADQX-UHFFFAOYSA-N 7-(2-methylhexan-2-yl)-9-(methylsulfanylmethoxy)-2,3,4a,9b-tetrahydro-1h-dibenzofuran-4-one Chemical compound C1=2C(OCSC)=CC(C(C)(C)CCCC)=CC=2OC2C1CCCC2=O JVISSGBRRMADQX-UHFFFAOYSA-N 0.000 claims description 3
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
• 206010006895 Cachexia Diseases 0.000 claims description 3
• 201000009030 Carcinoma Diseases 0.000 claims description 3
• 208000032612 Glial tumor Diseases 0.000 claims description 3
• 206010018338 Glioma Diseases 0.000 claims description 3
• 206010020772 Hypertension Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 3
• 208000007101 Muscle Cramp Diseases 0.000 claims description 3
• VDIPNVCWMXZNFY-UHFFFAOYSA-N N-methyl-beta-alanine Chemical compound CNCCC(O)=O VDIPNVCWMXZNFY-UHFFFAOYSA-N 0.000 claims description 3
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
• 208000007125 Neurotoxicity Syndromes Diseases 0.000 claims description 3
• 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
• 208000027868 Paget disease Diseases 0.000 claims description 3
• 230000000172 allergic effect Effects 0.000 claims description 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
• 208000022531 anorexia Diseases 0.000 claims description 3
• 239000007864 aqueous solution Substances 0.000 claims description 3
• 230000006793 arrhythmia Effects 0.000 claims description 3
• 206010003119 arrhythmia Diseases 0.000 claims description 3
• 208000010668 atopic eczema Diseases 0.000 claims description 3
• 125000003632 azulen-5-yl group Chemical group [H]C1=C([H])C2=C([H])C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
• 210000000988 bone and bone Anatomy 0.000 claims description 3
• 210000000481 breast Anatomy 0.000 claims description 3
• 206010061428 decreased appetite Diseases 0.000 claims description 3
• 239000002552 dosage form Substances 0.000 claims description 3
• 208000010932 epithelial neoplasm Diseases 0.000 claims description 3
• 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
• 208000027202 mammary Paget disease Diseases 0.000 claims description 3
• 230000002981 neuropathic effect Effects 0.000 claims description 3
• 238000007911 parenteral administration Methods 0.000 claims description 3
• 229960004063 propylene glycol Drugs 0.000 claims description 3
• 229910052701 rubidium Inorganic materials 0.000 claims description 3
• 210000001685 thyroid gland Anatomy 0.000 claims description 3
• 150000003626 triacylglycerols Chemical class 0.000 claims description 3
• XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims description 2
• KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims description 2
• HXIYMEWSKLDQCQ-UHFFFAOYSA-N 2-[[3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-yl]oxy]acetic acid Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C=C2OCC(O)=O HXIYMEWSKLDQCQ-UHFFFAOYSA-N 0.000 claims description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
• LHWFCDLDTCSLDB-UHFFFAOYSA-N [3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-yl] acetate Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C=C2OC(C)=O LHWFCDLDTCSLDB-UHFFFAOYSA-N 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 239000003995 emulsifying agent Substances 0.000 claims description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
• 208000030533 eye disease Diseases 0.000 claims description 2
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 2
• HUDLUWKIZNYYFJ-UHFFFAOYSA-N methyl 1-hydroxy-5a,6,7,8,9,9a-hexahydrodibenzofuran-3-carboxylate Chemical compound O1C2CCCCC2C2=C1C=C(C(=O)OC)C=C2O HUDLUWKIZNYYFJ-UHFFFAOYSA-N 0.000 claims description 2
• 239000002736 nonionic surfactant Substances 0.000 claims description 2
• 235000013772 propylene glycol Nutrition 0.000 claims description 2
• 210000002307 prostate Anatomy 0.000 claims description 2
• 229910052717 sulfur Inorganic materials 0.000 claims description 2
• 125000004430 oxygen atom Chemical group O* 0.000 claims 7
• 150000001721 carbon Chemical group 0.000 claims 5
• 229950008352 promoxolane Drugs 0.000 claims 4
• GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 claims 2
• 206010006458 Bronchitis chronic Diseases 0.000 claims 2
• 208000014675 Prion-associated disease Diseases 0.000 claims 2
• 239000004146 Propane-1,2-diol Substances 0.000 claims 2
• 230000036528 appetite Effects 0.000 claims 2
• 235000019789 appetite Nutrition 0.000 claims 2
• CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 claims 2
• 206010006451 bronchitis Diseases 0.000 claims 2
• 208000007451 chronic bronchitis Diseases 0.000 claims 2
• 239000006184 cosolvent Substances 0.000 claims 2
• 230000000302 ischemic effect Effects 0.000 claims 2
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
• ZETOHPSSBWBMED-UHFFFAOYSA-N 4-nitrooxybutanoic acid Chemical compound OC(=O)CCCO[N+]([O-])=O ZETOHPSSBWBMED-UHFFFAOYSA-N 0.000 claims 1
• WYXVVXPSGWVCOZ-UHFFFAOYSA-N 7,7-dimethyl-6,8,9,9a-tetrahydro-5aH-dibenzofuran-1-ol Chemical compound CC1(CC2C(C3=C(O2)C=CC=C3O)CC1)C WYXVVXPSGWVCOZ-UHFFFAOYSA-N 0.000 claims 1
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 201000005620 dermis tumor Diseases 0.000 claims 1
• 239000002563 ionic surfactant Substances 0.000 claims 1
• 239000000787 lecithin Substances 0.000 claims 1
• 229940067606 lecithin Drugs 0.000 claims 1
• 235000010445 lecithin Nutrition 0.000 claims 1
• AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 claims 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 208000033808 peripheral neuropathy Diseases 0.000 claims 1
• 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
• 239000003557 cannabinoid Substances 0.000 abstract description 41
• 229930003827 cannabinoid Natural products 0.000 abstract description 41
• 230000000202 analgesic effect Effects 0.000 abstract description 27
• 229940065144 cannabinoids Drugs 0.000 abstract description 24
• 230000002519 immonomodulatory effect Effects 0.000 abstract description 11
• 230000000324 neuroprotective effect Effects 0.000 abstract description 5
• 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
• 230000009286 beneficial effect Effects 0.000 abstract description 3
• 230000000144 pharmacologic effect Effects 0.000 abstract description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
• 241001465754 Metazoa Species 0.000 description 107
• 239000000203 mixture Substances 0.000 description 94
• 238000011282 treatment Methods 0.000 description 51
• 230000015572 biosynthetic process Effects 0.000 description 42
• 238000006243 chemical reaction Methods 0.000 description 42
• 230000000694 effects Effects 0.000 description 42
• 238000003786 synthesis reaction Methods 0.000 description 42
• 230000004044 response Effects 0.000 description 39
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
• IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical class C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 36
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
• 239000000460 chlorine Substances 0.000 description 36
• 239000003981 vehicle Substances 0.000 description 35
• 108020004414 DNA Proteins 0.000 description 33
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
• 239000002904 solvent Substances 0.000 description 33
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 31
• 102000005962 receptors Human genes 0.000 description 31
• 108020003175 receptors Proteins 0.000 description 31
• 102000018208 Cannabinoid Receptor Human genes 0.000 description 29
• 108050007331 Cannabinoid receptor Proteins 0.000 description 29
• 201000010099 disease Diseases 0.000 description 28
• 239000012267 brine Substances 0.000 description 27
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
• 238000009739 binding Methods 0.000 description 25
• 238000004440 column chromatography Methods 0.000 description 25
• 230000027455 binding Effects 0.000 description 24
• 210000002683 foot Anatomy 0.000 description 24
• 238000012360 testing method Methods 0.000 description 24
• 230000003110 anti-inflammatory effect Effects 0.000 description 21
• 239000011541 reaction mixture Substances 0.000 description 21
• 241000699670 Mus sp. Species 0.000 description 20
• 230000003187 abdominal effect Effects 0.000 description 20
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
• 230000005764 inhibitory process Effects 0.000 description 19
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
• 210000004027 cell Anatomy 0.000 description 18
• 102000053602 DNA Human genes 0.000 description 17
• 239000012044 organic layer Substances 0.000 description 17
• 108091034117 Oligonucleotide Proteins 0.000 description 16
• 108020004682 Single-Stranded DNA Proteins 0.000 description 16
• 230000037396 body weight Effects 0.000 description 16
• 229940079593 drug Drugs 0.000 description 16
• 238000007912 intraperitoneal administration Methods 0.000 description 15
• 108090000623 proteins and genes Proteins 0.000 description 15
• 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 14
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
• 229910052801 chlorine Inorganic materials 0.000 description 14
• 102000056693 human CNR2 Human genes 0.000 description 14
• 230000001404 mediated effect Effects 0.000 description 14
• 230000003389 potentiating effect Effects 0.000 description 14
• 230000009467 reduction Effects 0.000 description 14
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
• 230000014509 gene expression Effects 0.000 description 13
• 238000002347 injection Methods 0.000 description 13
• 239000007924 injection Substances 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 239000011734 sodium Substances 0.000 description 13
• 229910052938 sodium sulfate Inorganic materials 0.000 description 13
• 235000011152 sodium sulphate Nutrition 0.000 description 13
• 208000009935 visceral pain Diseases 0.000 description 13
• VNGQMWZHHNCMLQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-propan-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C VNGQMWZHHNCMLQ-UHFFFAOYSA-N 0.000 description 12
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
• 239000002158 endotoxin Substances 0.000 description 12
• 229920006008 lipopolysaccharide Polymers 0.000 description 12
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
• 239000000047 product Substances 0.000 description 12
• 239000007787 solid Substances 0.000 description 12
• 238000003756 stirring Methods 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 241000699666 Mus <mouse, genus> Species 0.000 description 11
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
• 239000000556 agonist Substances 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 239000007858 starting material Substances 0.000 description 11
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
• 230000007246 mechanism Effects 0.000 description 10
• 230000008961 swelling Effects 0.000 description 10
• 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 9
• 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 9
• 206010065390 Inflammatory pain Diseases 0.000 description 9
• 230000009471 action Effects 0.000 description 9
• 238000000540 analysis of variance Methods 0.000 description 9
• 208000035475 disorder Diseases 0.000 description 9
• 230000006698 induction Effects 0.000 description 9
• 238000004949 mass spectrometry Methods 0.000 description 9
• 239000012528 membrane Substances 0.000 description 9
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
• 206010030113 Oedema Diseases 0.000 description 8
• 239000000443 aerosol Substances 0.000 description 8
• 230000007423 decrease Effects 0.000 description 8
• 238000001035 drying Methods 0.000 description 8
• 239000003480 eluent Substances 0.000 description 8
• 210000002414 leg Anatomy 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 239000012074 organic phase Substances 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 8
• 230000000638 stimulation Effects 0.000 description 8
• 238000007920 subcutaneous administration Methods 0.000 description 8
• 125000001424 substituent group Chemical group 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 230000006399 behavior Effects 0.000 description 7
• 238000004587 chromatography analysis Methods 0.000 description 7
• 239000013058 crude material Substances 0.000 description 7
• 239000012043 crude product Substances 0.000 description 7
• 238000001704 evaporation Methods 0.000 description 7
• 230000008020 evaporation Effects 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• YNZFFALZMRAPHQ-SYYKKAFVSA-N 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]1[C@H](CCCO)CC[C@@H](O)C1 YNZFFALZMRAPHQ-SYYKKAFVSA-N 0.000 description 6
• 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• 229910019142 PO4 Inorganic materials 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 230000003042 antagnostic effect Effects 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 6
• 229960000590 celecoxib Drugs 0.000 description 6
• 239000010779 crude oil Substances 0.000 description 6
• SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 229960005181 morphine Drugs 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 208000004296 neuralgia Diseases 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 235000021317 phosphate Nutrition 0.000 description 6
• 239000000843 powder Substances 0.000 description 6
• 230000000069 prophylactic effect Effects 0.000 description 6
• 229960001755 resorcinol Drugs 0.000 description 6
• 238000000926 separation method Methods 0.000 description 6
• 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 5
• 241000218236 Cannabis Species 0.000 description 5
• 208000000094 Chronic Pain Diseases 0.000 description 5
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 5
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 5
• 208000005298 acute pain Diseases 0.000 description 5
• 230000001270 agonistic effect Effects 0.000 description 5
• 239000012458 free base Substances 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 238000002955 isolation Methods 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 208000021722 neuropathic pain Diseases 0.000 description 5
• 239000012299 nitrogen atmosphere Substances 0.000 description 5
• 239000003960 organic solvent Substances 0.000 description 5
• 239000010452 phosphate Substances 0.000 description 5
• 238000000159 protein binding assay Methods 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 5
• 229960001940 sulfasalazine Drugs 0.000 description 5
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 5
• 238000013268 sustained release Methods 0.000 description 5
• 239000012730 sustained-release form Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 4
• HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
• 229910004809 Na2 SO4 Inorganic materials 0.000 description 4
• 206010033799 Paralysis Diseases 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 239000000679 carrageenan Substances 0.000 description 4
• 235000010418 carrageenan Nutrition 0.000 description 4
• 229920001525 carrageenan Polymers 0.000 description 4
• 229940113118 carrageenan Drugs 0.000 description 4
• 210000001072 colon Anatomy 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 238000006073 displacement reaction Methods 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 230000003647 oxidation Effects 0.000 description 4
• 238000007254 oxidation reaction Methods 0.000 description 4
• 238000005191 phase separation Methods 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
• 238000010189 synthetic method Methods 0.000 description 4
• 230000005951 type IV hypersensitivity Effects 0.000 description 4
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 206010012735 Diarrhoea Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 108090000174 Interleukin-10 Proteins 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• 208000019430 Motor disease Diseases 0.000 description 3
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• 210000001015 abdomen Anatomy 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• 238000005804 alkylation reaction Methods 0.000 description 3
• 239000000730 antalgic agent Substances 0.000 description 3
• 239000012131 assay buffer Substances 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 230000036760 body temperature Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000002903 catalepsic effect Effects 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• PQANGXXSEABURG-UHFFFAOYSA-N cyclohex-2-en-1-ol Chemical compound OC1CCCC=C1 PQANGXXSEABURG-UHFFFAOYSA-N 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 230000002526 effect on cardiovascular system Effects 0.000 description 3
• 230000032050 esterification Effects 0.000 description 3
• 238000005886 esterification reaction Methods 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000007913 intrathecal administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000006742 locomotor activity Effects 0.000 description 3
• 238000002483 medication Methods 0.000 description 3
• LJDMYRNJYQKQFD-UHFFFAOYSA-N methyl azulene-5-carboxylate Chemical compound COC(=O)C1=CC=CC2=CC=CC2=C1 LJDMYRNJYQKQFD-UHFFFAOYSA-N 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 3
• 230000003040 nociceptive effect Effects 0.000 description 3
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
• 239000003208 petroleum Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 3
• 230000000704 physical effect Effects 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 210000003497 sciatic nerve Anatomy 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 230000008093 supporting effect Effects 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 239000002562 thickening agent Substances 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 231100000397 ulcer Toxicity 0.000 description 3
• 208000016261 weight loss Diseases 0.000 description 3
• 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 2
• KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
• RNVFYQUEEMZKLR-UHFFFAOYSA-N 1-carbomethoxy-3,5-dihydroxybenzene Natural products COC(=O)C1=CC(O)=CC(O)=C1 RNVFYQUEEMZKLR-UHFFFAOYSA-N 0.000 description 2
• SBRRDWKWIGRYCN-UHFFFAOYSA-N 2h-cyclopenta[g][1]benzofuran Chemical compound C1=CC2=CCOC2=C2C=CC=C21 SBRRDWKWIGRYCN-UHFFFAOYSA-N 0.000 description 2
• MLQIEDVHZPQCEP-UHFFFAOYSA-N 3,3-dimethyl-7-(2-methylhexan-2-yl)-9-(methylsulfanylmethoxy)-1,2,4a,9b-tetrahydrodibenzofuran-4-one Chemical compound C1=2C(OCSC)=CC(C(C)(C)CCCC)=CC=2OC2C1CCC(C)(C)C2=O MLQIEDVHZPQCEP-UHFFFAOYSA-N 0.000 description 2
• MXCHDXLYSWFKRQ-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCCC2O MXCHDXLYSWFKRQ-UHFFFAOYSA-N 0.000 description 2
• IWJTXAXEHZQQKB-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-6,7,8,9,10,10a-hexahydro-5ah-cyclohepta[b][1]benzofuran-1,6-diol Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCCCC2O IWJTXAXEHZQQKB-UHFFFAOYSA-N 0.000 description 2
• DPDJOSWZRZBGKE-UHFFFAOYSA-N 3-[[3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-yl]oxy]propane-1,2-diol Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C=C2OCC(O)CO DPDJOSWZRZBGKE-UHFFFAOYSA-N 0.000 description 2
• URZRWZMSDRJPTP-UHFFFAOYSA-N 3-pentyl-6,7,8,9,10,10a-hexahydro-5ah-cyclohepta[b][1]benzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2OC2C1CCCCC2O URZRWZMSDRJPTP-UHFFFAOYSA-N 0.000 description 2
• VOCRUTUQBPZTBX-UHFFFAOYSA-N 4-[2-[[3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-yl]oxy]ethyl]morpholine Chemical compound C=1C(C(C)(C)CCCC)=CC=2OC3CCCCC3C=2C=1OCCN1CCOCC1 VOCRUTUQBPZTBX-UHFFFAOYSA-N 0.000 description 2
• XJUOEZCUSLDLLH-UHFFFAOYSA-N 6-hydroxyimino-7,7-dimethyl-3-(2-methylhexan-2-yl)-5a,8,9,9a-tetrahydrodibenzofuran-1-ol Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCC(C)(C)C2=NO XJUOEZCUSLDLLH-UHFFFAOYSA-N 0.000 description 2
• ZWOIUTOBWYNGGM-UHFFFAOYSA-N 6-iodo-3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-ol Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCCC2I ZWOIUTOBWYNGGM-UHFFFAOYSA-N 0.000 description 2
• DKTMEQYYBKBYJZ-UHFFFAOYSA-N 7,7-dimethyl-3-(2-methylhexan-2-yl)-6,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCC(C)(C)C2O DKTMEQYYBKBYJZ-UHFFFAOYSA-N 0.000 description 2
• HVRSNRXJUGPVRU-UHFFFAOYSA-N 7,7-dimethyl-3-(2-methylhexan-2-yl)-6,8,9,9a-tetrahydro-5ah-dibenzofuran-1-ol Chemical compound O1C2CC(C)(C)CCC2C2=C1C=C(C(C)(C)CCCC)C=C2O HVRSNRXJUGPVRU-UHFFFAOYSA-N 0.000 description 2
• DJSAUXRCBZHTAX-UHFFFAOYSA-N 9-hydroxy-3,3-dimethyl-7-(2-methylhexan-2-yl)-1,2,4a,9b-tetrahydrodibenzofuran-4-one Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCC(C)(C)C2=O DJSAUXRCBZHTAX-UHFFFAOYSA-N 0.000 description 2
• VEWQFSJXAJGVAM-UHFFFAOYSA-N 9-hydroxy-7-(2-methylhexan-2-yl)-2,3,4a,9b-tetrahydro-1h-dibenzofuran-4-one Chemical compound C1=2C(O)=CC(C(C)(C)CCCC)=CC=2OC2C1CCCC2=O VEWQFSJXAJGVAM-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 229920000856 Amylose Polymers 0.000 description 2
• 241000913992 Aprion Species 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• 208000009132 Catalepsy Diseases 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• 206010052804 Drug tolerance Diseases 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
• 206010020565 Hyperaemia Diseases 0.000 description 2
• 208000004454 Hyperalgesia Diseases 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 229910010084 LiAlH4 Inorganic materials 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
• 206010029098 Neoplasm skin Diseases 0.000 description 2
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 238000010162 Tukey test Methods 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 206010047853 Waxy flexibility Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• KELXHQNGEAXFDG-UHFFFAOYSA-N [3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-yl] dihydrogen phosphate Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C=C2OP(O)(O)=O KELXHQNGEAXFDG-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000000118 anti-neoplastic effect Effects 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 159000000032 aromatic acids Chemical class 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 230000003375 cannabimimetic effect Effects 0.000 description 2
• 230000003293 cardioprotective effect Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000002361 compost Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000002939 deleterious effect Effects 0.000 description 2
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 150000004826 dibenzofurans Chemical class 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 229960004242 dronabinol Drugs 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 230000003628 erosive effect Effects 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 210000003608 fece Anatomy 0.000 description 2
• 238000003818 flash chromatography Methods 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 230000002178 gastroprotective effect Effects 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• 230000002631 hypothermal effect Effects 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 150000002576 ketones Chemical group 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 239000012280 lithium aluminium hydride Substances 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 229910001629 magnesium chloride Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 239000000693 micelle Substances 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 210000000214 mouth Anatomy 0.000 description 2
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
• VPVIQHJDKALBTJ-UHFFFAOYSA-N n-[3,3-dimethyl-7-(2-methylhexan-2-yl)-9-(methylsulfanylmethoxy)-1,2,4a,9b-tetrahydrodibenzofuran-4-ylidene]hydroxylamine Chemical compound C1=2C(OCSC)=CC(C(C)(C)CCCC)=CC=2OC2C1CCC(C)(C)C2=NO VPVIQHJDKALBTJ-UHFFFAOYSA-N 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 229910017604 nitric acid Inorganic materials 0.000 description 2
• 150000002825 nitriles Chemical class 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 description 2
• 150000002989 phenols Chemical class 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 239000002798 polar solvent Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 238000010149 post-hoc-test Methods 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 230000004224 protection Effects 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000001603 reducing effect Effects 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 229910001961 silver nitrate Inorganic materials 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 125000003107 substituted aryl group Chemical group 0.000 description 2
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 150000003573 thiols Chemical group 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
• CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
• 210000001364 upper extremity Anatomy 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Chemical compound CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
• SBTVLCPCSXMWIQ-UHFFFAOYSA-N (3,5-dimethylphenyl) carbamate Chemical compound CC1=CC(C)=CC(OC(N)=O)=C1 SBTVLCPCSXMWIQ-UHFFFAOYSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
• ZLYYJUJDFKGVKB-OWOJBTEDSA-N (e)-but-2-enedioyl dichloride Chemical compound ClC(=O)\C=C\C(Cl)=O ZLYYJUJDFKGVKB-OWOJBTEDSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• BASBVRCYYDGMHA-UHFFFAOYSA-N 1,2,3,4,4a,5a,10a,10b-octahydrocyclohepta[b][1]benzofuran-6-one Chemical compound C1CCCC2C1OC1C(C=CC=CC21)=O BASBVRCYYDGMHA-UHFFFAOYSA-N 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• YUIOPHXTILULQC-UHFFFAOYSA-N 1,4-Dithiane-2,5-diol Chemical compound OC1CSC(O)CS1 YUIOPHXTILULQC-UHFFFAOYSA-N 0.000 description 1
• WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
• FXYAHUSLDJDRLO-UHFFFAOYSA-N 1-(1-hydroxy-5a,6,7,8,9,9a-hexahydrodibenzofuran-3-yl)ethanone Chemical compound O1C2CCCCC2C2=C1C=C(C(=O)C)C=C2O FXYAHUSLDJDRLO-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 1
• GISHTFOSHZKUBZ-UHFFFAOYSA-N 2,3-dimethylcyclopent-2-en-1-ol Chemical compound CC1=C(C)C(O)CC1 GISHTFOSHZKUBZ-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• TXPJSTNMZHBTRF-UHFFFAOYSA-N 2-methylcyclopent-2-en-1-ol Chemical compound CC1=CCCC1O TXPJSTNMZHBTRF-UHFFFAOYSA-N 0.000 description 1
• BAKOSPCCAAZZSP-UHFFFAOYSA-N 2-tert-butylbenzene-1,3-diol Chemical compound CC(C)(C)C1=C(O)C=CC=C1O BAKOSPCCAAZZSP-UHFFFAOYSA-N 0.000 description 1
• QRXPBEJPKKERTR-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-2,4-dinitro-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-ol Chemical compound O1C2CCCCC2C2=C1C([N+]([O-])=O)=C(C(C)(C)CCCC)C([N+]([O-])=O)=C2O QRXPBEJPKKERTR-UHFFFAOYSA-N 0.000 description 1
• HMCRBYBBZWZUPI-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-2-nitro-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-ol Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C([N+]([O-])=O)=C2O HMCRBYBBZWZUPI-UHFFFAOYSA-N 0.000 description 1
• ZFASOOHAQPBBDY-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-4-nitro-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-ol Chemical compound C1CCCC2OC3=C([N+]([O-])=O)C(C(C)(C)CCCC)=CC(O)=C3C21 ZFASOOHAQPBBDY-UHFFFAOYSA-N 0.000 description 1
• GJTRJNGKVFBAHL-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-ol Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C=C2O GJTRJNGKVFBAHL-UHFFFAOYSA-N 0.000 description 1
• AEKKNWMCPXZLTN-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-5a,8,9,9a-tetrahydrodibenzofuran-1-ol Chemical compound O1C2C=CCCC2C2=C1C=C(C(C)(C)CCCC)C=C2O AEKKNWMCPXZLTN-UHFFFAOYSA-N 0.000 description 1
• KBABMICXFPNBQM-UHFFFAOYSA-N 3-(2-methylhexan-2-yl)-6,7,8,9-tetrahydrodibenzofuran-1-ol Chemical compound C1CCCC2=C1C1=C(O)C=C(C(C)(C)CCCC)C=C1O2 KBABMICXFPNBQM-UHFFFAOYSA-N 0.000 description 1
• TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
• VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 1
• RVDHYHWXIASNCB-UHFFFAOYSA-N 3-bromo-2,2,4,4-tetramethoxy-1,1-dimethylcyclohexane Chemical compound COC1(OC)CCC(C)(C)C(OC)(OC)C1Br RVDHYHWXIASNCB-UHFFFAOYSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• SZYOKKQBYLNJPH-UHFFFAOYSA-N 3-pentyl-6,7,8,9,10,10a-hexahydro-5ah-cyclohepta[b][1]benzofuran-1-ol Chemical compound O1C2CCCCCC2C2=C1C=C(CCCCC)C=C2O SZYOKKQBYLNJPH-UHFFFAOYSA-N 0.000 description 1
• LPDGWMLCUHULJF-UHFFFAOYSA-N 3-piperidin-1-ylpropanoic acid Chemical compound OC(=O)CCN1CCCCC1 LPDGWMLCUHULJF-UHFFFAOYSA-N 0.000 description 1
• KUAHEPXSQPFTGY-UHFFFAOYSA-N 3a-methyl-6-(2-methylhexan-2-yl)-1,2,3,8b-tetrahydrocyclopenta[b][1]benzofuran-8-ol Chemical compound OC1=CC(C(C)(C)CCCC)=CC2=C1C1CCCC1(C)O2 KUAHEPXSQPFTGY-UHFFFAOYSA-N 0.000 description 1
• YOOBXDZOVFJCNW-UHFFFAOYSA-N 4,4-dimethylcyclohex-2-en-1-ol Chemical compound CC1(C)CCC(O)C=C1 YOOBXDZOVFJCNW-UHFFFAOYSA-N 0.000 description 1
• NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
• KVXXEKIGMOEPSA-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOCC1C(O)=O KVXXEKIGMOEPSA-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• LRTRXDSAJLSRTG-UHFFFAOYSA-N 4-bromobutanoyl chloride Chemical compound ClC(=O)CCCBr LRTRXDSAJLSRTG-UHFFFAOYSA-N 0.000 description 1
• WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
• LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
• REOYOKXLUFHOBV-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidin-1-ylpyrazole-3-carboxamide;hydron;chloride Chemical compound Cl.CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 REOYOKXLUFHOBV-UHFFFAOYSA-N 0.000 description 1
• HRBWCBUDZSCBQZ-UHFFFAOYSA-N 5-[2-(2-phenylethyl)-1,3-dithiolan-2-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC(C2(CCC=3C=CC=CC=3)SCCS2)=C1 HRBWCBUDZSCBQZ-UHFFFAOYSA-N 0.000 description 1
• JGVWYJDASSSGEK-UHFFFAOYSA-N 5-methyl-2-propan-2-ylidenecyclohexan-1-ol Chemical compound CC1CCC(=C(C)C)C(O)C1 JGVWYJDASSSGEK-UHFFFAOYSA-N 0.000 description 1
• XOIZPYZCDNKYBW-UHFFFAOYSA-N 5-tert-butylbenzene-1,3-diol Chemical compound CC(C)(C)C1=CC(O)=CC(O)=C1 XOIZPYZCDNKYBW-UHFFFAOYSA-N 0.000 description 1
• XOURXNANHWFSHW-UHFFFAOYSA-N 7,7-dimethyl-3-[2-(2-phenylethyl)-1,3-dithiolan-2-yl]-6,8,9,9a-tetrahydro-5ah-dibenzofuran-1-ol Chemical compound C1C(C)(C)CCC(C2=C(O)C=3)C1OC2=CC=3C1(CCC=2C=CC=CC=2)SCCS1 XOURXNANHWFSHW-UHFFFAOYSA-N 0.000 description 1
• AMVCTGNPIZTPPL-UHFFFAOYSA-N 9a-methyl-3-(2-methylhexan-2-yl)-6,7,8,9-tetrahydro-5ah-dibenzofuran-1-ol Chemical compound O1C2CCCCC2(C)C2=C1C=C(C(C)(C)CCCC)C=C2O AMVCTGNPIZTPPL-UHFFFAOYSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 229910015900 BF3 Inorganic materials 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
• 102100028628 Bombesin receptor subtype-3 Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• ZLIVTMNXTYLJLP-UHFFFAOYSA-N Br[Br-]Br.CC[N+](CC)(CC)CC1=CC=CC=C1 Chemical compound Br[Br-]Br.CC[N+](CC)(CC)CC1=CC=CC=C1 ZLIVTMNXTYLJLP-UHFFFAOYSA-N 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• ZYXIZFQQQPPTAR-UHFFFAOYSA-N C1=CC=CC2=C1OC1=C(C=CC=CC21)O Chemical compound C1=CC=CC2=C1OC1=C(C=CC=CC21)O ZYXIZFQQQPPTAR-UHFFFAOYSA-N 0.000 description 1
• 101150084573 CPS5 gene Proteins 0.000 description 1
• 241000252983 Caecum Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 1
• 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 241000573484 Copsychus Species 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 102000001493 Cyclophilins Human genes 0.000 description 1
• 108010068682 Cyclophilins Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 101100288173 Enterococcus faecalis (strain ATCC 700802 / V583) prs1 gene Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• LTEQMZWBSYACLV-UHFFFAOYSA-N Hexylbenzene Chemical compound CCCCCCC1=CC=CC=C1 LTEQMZWBSYACLV-UHFFFAOYSA-N 0.000 description 1
• 101000695054 Homo sapiens Bombesin receptor subtype-3 Proteins 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000282339 Mustela Species 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 description 1
• 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 102000016202 Proteolipids Human genes 0.000 description 1
• 108010010974 Proteolipids Proteins 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 108010052164 Sodium Channels Proteins 0.000 description 1
• 102000018674 Sodium Channels Human genes 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 206010044038 Tooth erosion Diseases 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• CFMRIVODIXTERW-BHIFYINESA-N [(1r,2r,5r)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol Chemical compound COC1=CC(C(C)(C)CCCCCC)=CC(OC)=C1[C@H]1[C@H](C2(C)C)C[C@H]2C(CO)=C1 CFMRIVODIXTERW-BHIFYINESA-N 0.000 description 1
• ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
• QVLDSXIHLXFPLX-UHFFFAOYSA-N [3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-yl] 4-bromobutanoate Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C=C2OC(=O)CCCBr QVLDSXIHLXFPLX-UHFFFAOYSA-N 0.000 description 1
• SGSWUGFMZPXZFI-UHFFFAOYSA-N [3-(2-methylhexan-2-yl)-5a,6,7,8,9,9a-hexahydrodibenzofuran-1-yl] 4-nitrooxybutanoate Chemical compound O1C2CCCCC2C2=C1C=C(C(C)(C)CCCC)C=C2OC(=O)CCCO[N+]([O-])=O SGSWUGFMZPXZFI-UHFFFAOYSA-N 0.000 description 1
• DRUSRLANLKWFMA-UHFFFAOYSA-N [7,7-dimethyl-3-(2-methyloctan-2-yl)-6,8,9,9a-tetrahydro-5ah-dibenzofuran-1-yl] 3-(methylamino)propanoate Chemical compound O1C2CC(C)(C)CCC2C2=C1C=C(C(C)(C)CCCCCC)C=C2OC(=O)CCNC DRUSRLANLKWFMA-UHFFFAOYSA-N 0.000 description 1
• 230000000895 acaricidal effect Effects 0.000 description 1
• 239000000642 acaricide Substances 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000002313 adhesive film Substances 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 238000011360 adjunctive therapy Methods 0.000 description 1
• 239000003905 agrochemical Substances 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 150000001412 amines Chemical group 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 230000001760 anti-analgesic effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000003262 anti-osteoporosis Effects 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 210000004082 barrier epithelial cell Anatomy 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• YTLMWYRQBOOCDQ-UHFFFAOYSA-N benzo[a]azulene-4,9-diol Chemical compound C1=CC=C(C=2C1=CC1=C(C=CC=CC=21)O)O YTLMWYRQBOOCDQ-UHFFFAOYSA-N 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000012148 binding buffer Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical group 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000008199 coating composition Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• PSBABBDEUFNFKJ-UHFFFAOYSA-N cyclopent-2-en-1-ol Chemical compound OC1CCC=C1 PSBABBDEUFNFKJ-UHFFFAOYSA-N 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000036576 dermal application Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 150000002009 diols Chemical class 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 238000007907 direct compression Methods 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000001819 effect on gene Effects 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 239000002621 endocannabinoid Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
• BAVONGHXFVOKBV-UHFFFAOYSA-N exo-carveol Natural products CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 244000144992 flock Species 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 1
• RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 230000008938 immune dysregulation Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 239000002917 insecticide Substances 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 238000005339 levitation Methods 0.000 description 1
• 238000011694 lewis rat Methods 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 210000001853 liver microsome Anatomy 0.000 description 1
• 235000015250 liver sausages Nutrition 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 238000003801 milling Methods 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
• 229930003658 monoterpene Natural products 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
• PJSOCBVWZJGTHW-UHFFFAOYSA-N n-(1h-indazol-5-yl)-5-[3-methoxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-1,3-oxazol-2-amine Chemical compound C1=C(OC)C(OCCOCCOC)=CC=C1C(O1)=CN=C1NC1=CC=C(NN=C2)C2=C1 PJSOCBVWZJGTHW-UHFFFAOYSA-N 0.000 description 1
• IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000019079 negative regulation of cytokine secretion Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000004766 neurogenesis Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 239000004090 neuroprotective agent Substances 0.000 description 1
• 239000002581 neurotoxin Substances 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 238000006396 nitration reaction Methods 0.000 description 1
• 210000000929 nociceptor Anatomy 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 238000012346 open field test Methods 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 238000006146 oximation reaction Methods 0.000 description 1
• 230000008058 pain sensation Effects 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 235000011837 pasties Nutrition 0.000 description 1
• 210000004417 patella Anatomy 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• 229960003424 phenylacetic acid Drugs 0.000 description 1
• 239000003279 phenylacetic acid Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 239000000280 phytoalexin Substances 0.000 description 1
• 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 229920000137 polyphosphoric acid Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000007943 positive regulation of appetite Effects 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 230000001012 protector Effects 0.000 description 1
• 101150016674 prs2 gene Proteins 0.000 description 1
• 230000000506 psychotropic effect Effects 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• 229940048084 pyrophosphate Drugs 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000033458 reproduction Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 238000005488 sandblasting Methods 0.000 description 1
• 229930000044 secondary metabolite Natural products 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940048086 sodium pyrophosphate Drugs 0.000 description 1
• 238000000935 solvent evaporation Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229960002317 succinimide Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 150000003457 sulfones Chemical group 0.000 description 1
• 150000003462 sulfoxides Chemical group 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 150000003557 thiazoles Chemical class 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229960001479 tosylchloramide sodium Drugs 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 208000012991 uterine carcinoma Diseases 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1